COST-effectiveness of salmeterol/fluticasone propionate combination (Advair®) in uncontrolled asthma in Canada

Respiratory Medicine

Volumn 108, Issue 9, 2014, Pages 1292-1302

  Ismaila, Afisi S ^a,b   Risebrough, Nancy ^c   Li, Chunmei ^c   Corriveau, Diane ^a   Hawkins, Neil ^c   Mark Fitzgerald, J ^d   Su, Zhen ^a  

^a GLAXOSMITHKLINE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ICON PLC   (United Kingdom)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Asthma; Canada; Cost effectiveness; Quality adjusted life years; Salmeterol fluticasone propionate

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; DRUG COMBINATION; FLUTICASONE; FLUTICASONE, SALMETEROL DRUG COMBINATION; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CANADA; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEALTH CARE; HEALTH SERVICE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DOSE RESPONSE; DRUG COMBINATION; ECONOMICS; HEALTH CARE COST; META ANALYSIS; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; CANADA; CHILD; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84912522911     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.06.005     Document Type: Article

References (56)

1. Statistics Canada Asthma, by age group and sex (number of persons) [ tables] 2013 June 17 Statistics Canada Ottawa Available from: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/health49a-eng.htm [cited 2014 May 12]
2. Statistics Canada Asthma 2010 [health fact sheets] 2011 July 28 Statistics Canada Ottawa Available from: http://www.statcan.gc.ca/pub/82-625-x/2011001/article/11458-eng.htm [cited 2011 Nov 8]
3. J.M. FitzGerald, L.P. Boulet, R.A. McIvor, S. Zimmerman, and K.R. Chapman Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study Can Respir J 13 5 2006 Jul 253 259
4. R.A. McIvor, L.P. Boulet, J.M. FitzGerald, S. Zimmerman, and K.R. Chapman Asthma control in Canada Can Fam Physician 53 4 2007 Apr 1 672 677
5. P. Demoly, K. Annunziata, E. Gubba, and L. Adamek Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years Eur Respir Rev 21 123 2012 Mar 1 66 74
6. Y. Chen, H. Johansen, S. Thillaiampalam, and C. Sambell Asthma. (Statistics Canada, catalogue 82-003) Health Rep 16 2 2005 43 46
7. T.W. Guilbert, C. Garris, P. Jhingran, M. Bonafede, K.J. Tomaszewski, and T. Bonus Asthma that is not well-controlled is associated with increased healthcare utilization and decreased quality of life J Asthma 48 2 2011 Mar 126 132
8. R.J. Adams, D.H. Wilson, A.W. Taylor, A. Daly, E. Tursan d'Espaignet, and E. Dal Grande Psychological factors and asthma quality of life: a population based study Thorax 59 11 2004 Nov 1 930 935
9. P. Demoly, P. Paggiaro, V. Plaza, S.C. Bolge, H. Kannan, and B. Sohier Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK Eur Respir Rev 18 112 2009 Jun 105 112
10. W.M. Vollmer, L.E. Markson, E. O'Connor, E.A. Frazier, M. Berger, and A.S. Buist Association of asthma control with health care utilization: a prospective evaluation Am J Respir Crit Care Med 165 2 2002 Jan 15 195 199
11. Global Initiatives for Asthma (GINA) Global strategy for asthma management and prevention 2013 May Global Initiatives for Asthma (GINA) Available from: http://www.ginasthma.org/
12. M.D. Lougheed, C. Lemiere, S.D. Dell, F.M. Ducharme, J.M. FitzGerald, and R. Leigh Canadian Thoracic Society Asthma Management Continuum-2010 Consensus for children six years of age and over, and adults Can Respir J 17 1 2010 Jan 15 24
13. M.D. Lougheed, C. Lemiere, F.M. Ducharme, C. Licskai, S.D. Dell, and B.H. Rowe Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults Can Respir J 19 2 2012 Mar 127 164
14. British Guidelines on the Management of Asthma, revised 2012. Scottish Intercollegiate Guideline Network (SIGN) and British Thoracic Society (BTS) 2012 Available from: http://www.sign.ac.uk/guidelines/fulltext/101/index.html
15. F.M. Ducharme, M. Ni Chroinin, I. Greenstone, and T.J. Lasserson Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma Cochrane Database Syst Rev 4 2010 Apr 14 CD005533 10.1002/14651858.CD005533.pub2
16. J. Shepherd, G. Rogers, R. Anderson, C. Main, J. Thompson-Coon, and D. Hartwell Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over Health Technol Assess 12 19 2008 May iii iiv 1-360
17. B. Jonsson, F. Berggren, K. Svensson, and P.M. O'Byrne An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma Respir Med 98 11 2004 Nov 1146 1154
18. F. Andersson, E. Stahl, P.J. Barnes, C.G. Lofdahl, P.M. O'Byrne, and R.A. Pauwels Adding formoterol to budesonide in moderate asthma - health economic results from the FACET study Respir Med 95 6 2001 Jun 505 512
19. A.H. Briggs, J. Bousquet, M.V. Wallace, W.W. Busse, T.J. Clark, and S.E. Pedersen Cost-effectiveness of asthma control: an economic appraisal of the GOAL study Allergy 61 5 2006 May 531 536
20. I. Doull, D. Price, M. Thomas, N. Hawkins, E. Stamuli, and M. Tabberer Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma Curr Med Res Opin 23 5 2007 May 1147 1159
21. G. Johansson, M.J. Price, and S. Sondhi Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100ug vs fluticasone propionate 100ug in adults and adolescents with asthma III: results Pharmacoeconomics 16 1999 15 21
22. M.J. Price, and A.H. Briggs Development of an economic model to assess the cost effectiveness of asthma management strategies Pharmacoeconomics 20 3 2002 183 194
23. B. Lundback, C. Jenkins, M.J. Price, and M.A. Thwaites Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 mcg twice daily and budesonide 800 mcg twice daily in the treatment of adults and adolescents with asthma Respir Med 94 7 2000 Jul 724 732
24. M. Palmqvist, M.J. Price, and S. Sondhi Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250ug vs fluticasone propionate 250ug in adults and adolescents with asthma IV: results Pharmacoeconomics 16 S2 1999 23 28
25. W.R. Pieters, B. Lundback, S. Sondhi, M.J. Price, and R.M.A. Thwaites Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500ug vs fluticasone propionate 500ug in patients with corticosteroid-dependent asthma V: results Pharmacoeconomics 16 S5 1999 29 34
26. K. Ericsson, T.A. Bantje, R.M. Huber, S. Borg, and E.D. Bateman Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma Respir Med 100 4 2006 Apr 1 586 594
27. Y.C.T. Shih, J. Mauskopf, and R.A. Borker Cost-effectiveness analysis of first-line controller therapies for persistent asthma Pharmacoeconomics 25 7 2007
28. E.D. Bateman, H.A. Boushey, J. Bousquet, W.W. Busse, T.J. Clark, and R.A. Pauwels Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study Am J Respir Crit Care Med 170 8 2004 Oct 15 836 844
29. Schedule of Benefits for Physician Services 2011 Ontario Ministry of Health and Long-Term Care Available from: http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv-mn.html
30. Ontario Drug Benefit (ODB) formulary 2011 Ontario Ministry of Health and Long-Term Care Available from https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp
31. Alberta Health and Wellness Alberta case cost report, for 2006/2007 hospital activity 2009 Government of Alberta, Health and Wellness Available from: www.health.alberta.ca/documents/Case-Cost-Hospital-06-07.pdf
32. E. Miller, and J.M. FitzGerald Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation Can J Clin Pharmacol 15 2 2008 e165 e176
33. Statistics Canada Consumer price index 2011 Statistics Canada Available from: http://www40.statcan.gc.ca/l01/cst01/cpis13a-eng.htm [cited 2011 Nov]
34. S.P. Peters, N. Anthonisen, M. Castro, J.T. Holbrook, C.G. Irvin, and L.J. Smith Randomized comparison of strategies for reducing treatment in mild persistent asthma N Engl J Med 356 20 2007 May 17 2027 2039
35. A. Chuchalin, L. Jacques, and L. Frith Salmeterol/fluticasone propionate via Diskus once daily versus fluticasone propionate twice daily in patients with mild asthma not previously receiving maintenance corticosteroids Clin Drug Investig 28 3 2008 169 181
36. B.J. de, L. Ogorodova, R. Klink, I. Sidorenko, A. Valiulis, and J. Hofman Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children Pediatr Allergy Immunol 20 8 2009 Dec 763 771
37. M. Gappa, W. Zachgo, B.A. von, W. Kamin, C. Stern-Strater, and G. Steinkamp Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED) Pediatr Pulmonol 44 11 2009 Nov 1132 1142
38. R.F. Lemanske Jr., D.T. Mauger, C.A. Sorkness, D.J. Jackson, S.J. Boehmer, and F.D. Martinez Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids N Engl J Med 362 11 2010 Mar 18 975 985
39. A.A. Vaessen-Verberne, N.J. van den Berg, J.C. van Nierop, H.J. Brackel, G.P. Gerrits, and W.C. Hop Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma Am J Respir Crit Care Med 182 10 2010 Nov 15 1221 1227
40. C.S. Murray, A. Custovic, L.A. Lowe, S. Aldington, M. Williams, and R. Beasley Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma Allergy Asthma Proc 31 5 2010 Sep 415 421
41. K.L. Clearie, L. McKinlay, P.A. Williamson, P. Hopkinson, K.T. Meldrum, and B.J. Lipworth P172-Fluticasone/salmeterol combination confers significant benefits in smoking asthmatics Thorax 65 Suppl. 4 2010 Dec 1 A150 A151
42. S.M. Koenig, J.J. Murray, J. Wolfe, L. Andersen, S. Yancey, and B. Prillaman Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respir Med 102 5 2008 May 665 673
43. Ontario case costing initiative (OCCI) 2011 Ontario Ministry of Health and Long-Term Care Available from: http://www.occp.com/mainPage.htm
44. Guidelines for the economic evaluations of health technologies: Canada 3rd ed. 2006 Canadian Agency for Drugs and Technologies in Health (CADTH) Available from: http://cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf
45. K. Bond, D. Coyle, and K. O'Gorman Long-acting beta2-agonist and inhaled corticosteroid combination therapy for adult persistent asthma: systematic review of clinical outcomes and economic evaluation [Technologu report number 122] 2009 Canadian Agency for Drugs and Technologies in Health Ottawa Available from: http://www.cadth.ca/en/products/health-technology-assessment/publication/941
46. E.D. Bateman, V. Silins, and M. Bogolubov Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma Respir Med 95 2 2001 Feb 136 146
47. R.A. Nathan, A. Rooklin, L. Schoaf, C. Scott, A. Ellsworth, and K. House Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study Clin Ther 28 1 2006 Jan 73 85
48. G. Shapiro, W. Lumry, and J. Wolfe Combined salmeterol 50mcg and fluticasone propionate 250 mcg in the diskus device for the treatment of asthma Am J Respir Crit Care Med 161 2000 527 534
49. M. Aubier, W.R. Pieters, N.J. Schlosser, and K.O. Steinmetz Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma Respir Med 93 12 1999 Dec 876 884
50. J.A. Van Noord, H. Lill, and T. Carillo Diaz Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/500mcg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the Diskus in patients with moderate to severe asthma Clin Drug Investig 21 2001 243 255
51. GSK study registry 2011 GSK Clinical Trials Register Available from: http://www.gsk-clinicalstudyregister.com/
52. K.C. Bergmann, L. Lindemann, R. Braun, and G. Steinkamp Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma Swiss Med Wkly 134 3-4 2004 Jan 24 50 58
53. W. Busse, S.M. Koenig, J. Oppenheimer, S.A. Sahn, S.W. Yancey, and D. Reilly Steroid-sparing effects of fluticasone propionate 100 mcg and salmeterol 50 mcg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 mcg administered twice daily J Allergy Clin Immunol 111 1 2003 Jan 1 57 65
54. J. Baraniuk, J.J. Murray, R.A. Nathan, W.E. Berger, M. Johnson, and L.D. Edwards Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma Chest 116 3 1999 Sep 625 632
55. M. Kavuru, J. Melamed, G. Gross, C. Laforce, K. House, and B. Prillaman Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial J Allergy Clin Immunol 105 6 Pt 1 2000 Jun 1108 1116
56. P.W. Ind, N.R. Dal, N.C. Colman, C.P. Fletcher, D. Browning, and M.H. James Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma Respir Med 97 5 2003 May 555 562